Millennium Management LLC trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 61.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 277,052 shares of the company’s stock after selling 437,953 shares during the quarter. Millennium Management LLC owned approximately 0.30% of Neurocrine Biosciences worth $24,965,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital Investment Advisory Services LLC purchased a new stake in shares of Neurocrine Biosciences in the second quarter valued at about $43,000. NEXT Financial Group Inc raised its position in shares of Neurocrine Biosciences by 89.8% during the 2nd quarter. NEXT Financial Group Inc now owns 560 shares of the company’s stock worth $47,000 after purchasing an additional 265 shares during the last quarter. Tower Research Capital LLC TRC raised its position in shares of Neurocrine Biosciences by 70.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 595 shares of the company’s stock worth $51,000 after purchasing an additional 246 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new position in shares of Neurocrine Biosciences during the 3rd quarter worth approximately $67,000. Finally, Golden State Wealth Management LLC lifted its stake in Neurocrine Biosciences by 100.0% in the 2nd quarter. Golden State Wealth Management LLC now owns 1,000 shares of the company’s stock valued at $84,000 after buying an additional 500 shares in the last quarter. Institutional investors own 97.13% of the company’s stock.
Several equities analysts have weighed in on the company. BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, November 8th. Royal Bank of Canada set a $118.00 price target on Neurocrine Biosciences and gave the stock a “buy” rating in a report on Friday, September 6th. Piper Jaffray Companies upped their price objective on Neurocrine Biosciences from $111.00 to $116.00 in a research report on Tuesday, November 5th. Zacks Investment Research lowered Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, November 20th. Finally, TheStreet upgraded Neurocrine Biosciences from a “c+” rating to a “b” rating in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have assigned a buy rating to the company’s stock. Neurocrine Biosciences presently has an average rating of “Buy” and an average target price of $105.72.
NBIX stock opened at $116.76 on Tuesday. The stock has a market capitalization of $10.74 billion, a price-to-earnings ratio of 530.73, a price-to-earnings-growth ratio of 5.90 and a beta of 1.24. The company has a quick ratio of 6.99, a current ratio of 7.08 and a debt-to-equity ratio of 0.83. Neurocrine Biosciences, Inc. has a 52-week low of $64.72 and a 52-week high of $118.42. The stock’s fifty day simple moving average is $105.65 and its 200-day simple moving average is $93.62.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Monday, November 4th. The company reported $0.56 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.63 by ($0.07). Neurocrine Biosciences had a net margin of 3.12% and a return on equity of 5.67%. The business had revenue of $222.09 million during the quarter, compared to analyst estimates of $211.31 million. During the same quarter in the previous year, the company posted $0.52 earnings per share. The business’s revenue for the quarter was up 46.3% compared to the same quarter last year. As a group, analysts anticipate that Neurocrine Biosciences, Inc. will post 0.82 earnings per share for the current fiscal year.
In other Neurocrine Biosciences news, insider Malcolm Lloyd-Smith sold 9,956 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $90.85, for a total transaction of $904,502.60. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Julie Cooke sold 987 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $88.56, for a total transaction of $87,408.72. The disclosure for this sale can be found here. Insiders sold a total of 46,131 shares of company stock valued at $4,745,275 in the last 90 days. 4.30% of the stock is owned by company insiders.
Neurocrine Biosciences Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.
Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.